3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression : ARF6 regulates ERK1/2 pathway by inhibiting DUSP6

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          ERK1/2 are essential proteins mediating mitogen-activated protein kinase signaling downstream of RAS in pancreatic adenocarcinoma (PDAC). Our previous study reveals that ARF6 plays a positive regulatory role in ERK1/2 pathway in a feedback loop manner. A significant part of the literature on ARF6 has emphasized its oncogenic effect as an essential downstream molecule of ERK1/2, and no research has been done on the regulation mechanisms of the feedback loop between ARF6 and the ERK1/2 signaling pathway. In the present study, we explore the gene network downstream of ARF6 and find that DUSP6 may be the critical signal molecule in the positive feedback loop between ARF6 and ERK1/2. Specifically, to elucidate the negative correlations between ARF6 and DUSP6 in pancreatic cancer, we examine their expressions in pancreatic cancer tissues by immunohistochemical staining. Then the impact of DUSP6 on the proliferation and apoptosis of PDAC cells are investigated by gain-of-function and loss-of-function approaches. Mechanism explorations uncover that ARF6 suppresses the expression of DUSP6, which is responsible for the dephosphorylation of ERK1/2. Altogether, these results indicate that DUSP6 plays a tumor-suppressive role and acts as an intermediate molecule between ARF6 and ERK1/2 in PDAC cells, thereby forming a positive feedback loop.

          Related collections

          Most cited references30

          • Record: found
          • Abstract: found
          • Article: not found

          Cancer statistics, 2020

          Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States and compiles the most recent data on population-based cancer occurrence. Incidence data (through 2016) were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2017) were collected by the National Center for Health Statistics. In 2020, 1,806,590 new cancer cases and 606,520 cancer deaths are projected to occur in the United States. The cancer death rate rose until 1991, then fell continuously through 2017, resulting in an overall decline of 29% that translates into an estimated 2.9 million fewer cancer deaths than would have occurred if peak rates had persisted. This progress is driven by long-term declines in death rates for the 4 leading cancers (lung, colorectal, breast, prostate); however, over the past decade (2008-2017), reductions slowed for female breast and colorectal cancers, and halted for prostate cancer. In contrast, declines accelerated for lung cancer, from 3% annually during 2008 through 2013 to 5% during 2013 through 2017 in men and from 2% to almost 4% in women, spurring the largest ever single-year drop in overall cancer mortality of 2.2% from 2016 to 2017. Yet lung cancer still caused more deaths in 2017 than breast, prostate, colorectal, and brain cancers combined. Recent mortality declines were also dramatic for melanoma of the skin in the wake of US Food and Drug Administration approval of new therapies for metastatic disease, escalating to 7% annually during 2013 through 2017 from 1% during 2006 through 2010 in men and women aged 50 to 64 years and from 2% to 3% in those aged 20 to 49 years; annual declines of 5% to 6% in individuals aged 65 years and older are particularly striking because rates in this age group were increasing prior to 2013. It is also notable that long-term rapid increases in liver cancer mortality have attenuated in women and stabilized in men. In summary, slowing momentum for some cancers amenable to early detection is juxtaposed with notable gains for other common cancers.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Pancreatic cancer

            Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised. High quality computed tomography with intravenous contrast using a dual phase pancreatic protocol is typically the best method to detect a pancreatic tumour and to determine surgical resectability. Endoscopic ultrasound is an increasingly used complementary staging modality which also allows for diagnostic confirmation when combined with fine needle aspiration. Patients with pancreatic cancer are often divided into one of four categories based on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is also an important consideration. Surgical resection represents the only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes in these patients. Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease. Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Therapeutic developments in pancreatic cancer: current and future perspectives

              The overall 5-year survival for pancreatic cancer has changed little over the past few decades, and pancreatic cancer is predicted to be the second leading cause of cancer-related mortality in the next decade in Western countries. The past few years, however, have seen improvements in first-line and second-line palliative therapies and considerable progress in increasing survival with adjuvant treatment. The use of biomarkers to help define treatment and the potential of neoadjuvant therapies also offer opportunities to improve outcomes. This Review brings together information on achievements to date, what is working currently and where successes are likely to be achieved in the future. Furthermore, we address the questions of how we should approach the development of pancreatic cancer treatments, including those for patients with metastatic, locally advanced and borderline resectable pancreatic cancer, as well as for patients with resected tumours. In addition to embracing newer strategies comprising genomics, stromal therapies and immunotherapies, conventional approaches using chemotherapy and radiotherapy still offer considerable prospects for greater traction and synergy with evolving concepts.
                Bookmark

                Author and article information

                Journal
                Acta Biochim Biophys Sin (Shanghai)
                Acta Biochim Biophys Sin (Shanghai)
                ABBS
                Acta Biochimica et Biophysica Sinica
                Oxford University Press
                1672-9145
                1745-7270
                19 August 2022
                October 2022
                19 August 2022
                : 54
                : 10
                : 1431-1440
                Affiliations
                [1 ] orgnameDepartment of Hepatopancreatobiliary Surgery orgnamethe Third Affiliated Hospital of Soochow University Changzhou 213000 China
                [2 ] orgnameDepartment of Pancreatic Surgery orgnameFudan University Shanghai Cancer Center Shanghai 200032 China
                Author notes
                [ † ]

                These authors contributed equally to this work.

                Correspondence address. Tel: +86-381-3587333; E-mail: (X.C) / Tel: +86-21-81602085; E-mail: (Y.Q.) czcxm007@126.comqinyi@fudanpci.org
                Article
                10.3724/abbs.2022111
                9827993
                36017891
                0aef7eb6-15e1-4c67-b00d-c01b96359849
                © The Author(s) 2021.

                This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

                History
                : 21 December 2021
                : 18 April 2022
                Funding
                Funded by: the grants from the National Natural Science Foundation of China
                Award ID: No.
                Award ID: 81602054
                Funded by: the Applied Basic Research of Changzhou Technology Bureau
                Award ID: No.
                Award ID: CJ20190093
                Funded by: the Youth Science and Technology Project of Changzhou Health Commission
                Award ID: No.
                Award ID: QN202101
                Funded by: the Major Science and Technology Project of Changzhou Health Commission
                Award ID: No.
                Award ID: ZD201906
                Funded by: and the ‘‘Six One Project’’ Top-notch Talent Research Project of High-level Health Talents of Jiangsu Provincial Health Commission
                Award ID: No.
                Award ID: LGY2019022
                This work was supported by the grants from the National Natural Science Foundation of China (No. 81602054), the Applied Basic Research of Changzhou Technology Bureau (No. CJ20190093), the Youth Science and Technology Project of Changzhou Health Commission (No. QN202101), the Major Science and Technology Project of Changzhou Health Commission (No. ZD201906), and the ‘‘Six One Project’’ Top-notch Talent Research Project of High-level Health Talents of Jiangsu Provincial Health Commission (No. LGY2019022).
                Categories
                Research Article
                Custom metadata
                B Xiao, Y Zhang, Z Lu, W Chen, Y An, G Zu, X Xu, et al.A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression. Acta Biochim Biophys Sin, 2022, 54, 1431-1440, https://doi.org/10.3724/abbs.2022111
                2022/8/16 10:27:16
                Xiao
                B Xiao, Y Zhang, Z Lu, W Chen, Y An, G Zu, X Xu, et al.
                A positive feedback loop of ARF6 activates ERK1/2 signaling pathway via DUSP6 silencing to promote pancreatic cancer progression

                erk1/2 pathway,arf6,dusp6,pancreatic adenocarcinoma
                erk1/2 pathway, arf6, dusp6, pancreatic adenocarcinoma

                Comments

                Comment on this article